Our findings suggest that MARCH5 participates in the pathological cardiac hypertrophy by regulating the Akt/mTOR/Gsk‐3β/GATA4 pathway, positioning it as a promising therapeutic target for cardiac hypertrophy. This evidence concerns the gene MTOR and cardiac hypertrophy.